Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets

Glioblastoma (GBM), a WHO-defined Grade IV astrocytoma, is the most common and aggressive CNS malignancy. Despite current treatment modalities, the survival time remains dismal. The main cause of mortality in patients with this disease is reoccurrence of the malignancy, which is attributed to treatment-resistant cancer stem cells within and surrounding the primary tumor. Inclusion of novel therapies, such as immuno- and DNA-based therapy, may provide better means of treating GBM. Furthermore, manipulation of recently discovered non-coding microRNAs, some of which regulate tumor growth through the development and maintenance of GBM stem cells, could provide new prospective therapies. Studies conducted by The Cancer Genome Atlas (TCGA) also demonstrate the role of molecular pathways, specifically the activated PI3K/AKT/mTOR pathway, in GBM tumorigenesis. Inhibition of the aforementioned pathway may provide a more direct and targeted method to GBM treatment. The combination of these treatment modalities may provide an innovative therapeutic approach for the management of GBM.

[1]  A. Dicker,et al.  Improving prognosis of glioblastoma in the 21st century: Who has benefited most? , 2012, Cancer.

[2]  K. Camphausen,et al.  Physiologic Oxygen Concentration Enhances the Stem-Like Properties of CD133+ Human Glioblastoma Cells In vitro , 2009, Molecular Cancer Research.

[3]  Ailin Li,et al.  Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma , 2012, Journal of Experimental & Clinical Cancer Research.

[4]  P. Kleihues,et al.  Intratumoral Patterns of Genomic Imbalance in Glioblastomas , 2010, Brain pathology.

[5]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[6]  Z. Ram,et al.  Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[7]  S. Nelson,et al.  Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy , 2010, Clinical Cancer Research.

[8]  A. Gudkov,et al.  The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway , 2010, Aging.

[9]  G. Basso,et al.  Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. , 2013, Biochemical pharmacology.

[10]  Y. Yonekawa,et al.  Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. , 1996, Brain pathology.

[11]  E. Chiocca,et al.  Strategies in Gene Therapy for Glioblastoma , 2013, Cancers.

[12]  D. Schiff,et al.  Oncogenic effects of miR-10b in glioblastoma stem cells , 2013, Journal of Neuro-Oncology.

[13]  Daming Zhang,et al.  MicroRNA-153 is tumor suppressive in glioblastoma stem cells , 2013, Molecular Biology Reports.

[14]  T. Ekström,et al.  Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. , 2003, Experimental cell research.

[15]  J. Engh,et al.  Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α , 2009, Oncogene.

[16]  T. Kubota,et al.  A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma , 2011, Journal of Clinical Neuroscience.

[17]  P. Canoll,et al.  PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma. , 2012, Human molecular genetics.

[18]  D. Wion,et al.  Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. , 2007, Cancer letters.

[19]  R. Murali,et al.  Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. , 2013, Oncology reports.

[20]  L. Zitvogel,et al.  Trial watch , 2013 .

[21]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[22]  Seung Il Kim,et al.  Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy. , 2013, Omics : a journal of integrative biology.

[23]  P. Kleihues,et al.  The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.

[24]  C. Richichi,et al.  Current Strategies for Identification of Glioma Stem Cells: Adequate or Unsatisfactory? , 2012, Journal of oncology.

[25]  Mei Mei,et al.  Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status , 2010, Laboratory Investigation.

[26]  K. Kissa,et al.  Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  Jian Wang,et al.  Glioma cell populations grouped by different cell type markers drive brain tumor growth. , 2010, Cancer research.

[28]  P. Lichter,et al.  Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients , 2008, Clinical Cancer Research.

[29]  Keiji Suzuki,et al.  miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. , 2010, Cancer letters.

[30]  B. Ding,et al.  Prominin 1/CD133 Endothelium Sustains Growth of Proneural Glioma , 2013, PloS one.

[31]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[32]  M. Mizoguchi,et al.  Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. , 2012, Neuro-oncology.

[33]  Wei-jiang Zhao.  Comparison of L1 expression and secretion in glioblastoma and neuroblastoma cells. , 2012, Oncology letters.

[34]  A. Engel,et al.  PloS One 2012 , 2015 .

[35]  L. Liau,et al.  Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients , 2012, PloS one.

[36]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[37]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[38]  S. Asuthkar,et al.  Epigenetic Regulation of miRNA-211 by MMP-9 Governs Glioma Cell Apoptosis, Chemosensitivity and Radiosensitivity , 2012, Oncotarget.

[39]  P. Canoll,et al.  MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. , 2013, Human molecular genetics.

[40]  L. Chodosh,et al.  mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. , 2009, Cell stem cell.

[41]  J. Martinez-Climent,et al.  Involvement of miRNAs in the Differentiation of Human Glioblastoma Multiforme Stem-Like Cells , 2013, PloS one.

[42]  Toshihiko Wakabayashi,et al.  Immunohistochemical analysis‐based proteomic subclassification of newly diagnosed glioblastomas , 2012, Cancer science.

[43]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[44]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[45]  S. Hansen,et al.  What is the clinical value of cancer stem cell markers in gliomas? , 2013, International journal of clinical and experimental pathology.

[46]  Bahauddeen M. Alrfaei,et al.  microRNA-100 Targets SMRT/NCOR2, Reduces Proliferation, and Improves Survival in Glioblastoma Animal Models , 2013, PloS one.

[47]  R. Sciot,et al.  Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[48]  S. Weiss,et al.  Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens , 2009, Stem cells.

[49]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[50]  Xiaoqin Zhang,et al.  MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. , 2012, Anticancer research.

[51]  C. Kang,et al.  A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. , 2014, Oncology reports.

[52]  M. Karsy,et al.  Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. , 2011, Advances in enzyme regulation.

[53]  R. Warnick,et al.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.

[54]  W. Ding,et al.  Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor‐β , 2010, Hepatology.

[55]  N. Saijo,et al.  mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. , 2009, Cancer research.

[56]  G. Maira,et al.  Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution , 2009, Oncogene.

[57]  M. Blagosklonny,et al.  Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence , 2009, Cell cycle.

[58]  F. Moolten.  Drug sensitivity ("suicide") genes for selective cancer chemotherapy. , 1994, Cancer gene therapy.

[59]  K. Tachibana,et al.  MEK‐ERK Signaling Dictates DNA‐Repair Gene MGMT Expression and Temozolomide Resistance of Stem‐Like Glioblastoma Cells via the MDM2‐p53 Axis , 2011, Stem cells.

[60]  Michael N. Hall,et al.  TOR signalling in bugs, brain and brawn , 2003, Nature Reviews Molecular Cell Biology.

[61]  Jian Wang,et al.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells , 2008, International journal of cancer.

[62]  Moolten Fl.  Drug sensitivity ("suicide") genes for selective cancer chemotherapy. , 1994 .

[63]  A. Tolcher,et al.  The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[64]  Wei Yan,et al.  MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. , 2012, Oncology reports.

[65]  Pieter Wesseling,et al.  International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.

[66]  Manfred Westphal,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[67]  J. Huse,et al.  Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. , 2014, Cell stem cell.

[68]  P. Lowenstein,et al.  Adenovirus Binding to the Coxsackievirus and Adenovirus Receptor or Integrins Is Not Required To Elicit Brain Inflammation but Is Necessary To Transduce Specific Neural Cell Types , 2002, Journal of Virology.

[69]  Yongming Qiu,et al.  MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. , 2014, Experimental cell research.

[70]  S. Ogawa,et al.  miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme , 2013, Oncogene.

[71]  R. McLendon,et al.  EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma , 2009, Brain pathology.

[72]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[73]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[74]  J. Baselga,et al.  TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. , 2010, Cancer cell.

[75]  David García-Dorado,et al.  TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. , 2009, Cancer cell.

[76]  Yongming Qiu,et al.  C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. , 2013, Biochemical and biophysical research communications.

[77]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[78]  S. Lewandowsky.  PLOS ONE 2013 , 2015 .

[79]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[81]  Eric C. Holland,et al.  Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma , 2010, Nature Reviews Cancer.

[82]  T. Mikkelsen,et al.  MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1 , 2013, Oncotarget.

[83]  T. Wurdinger,et al.  MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators , 2008, Molecular and Cellular Biology.

[84]  L. Zitvogel,et al.  Trial watch , 2012, Oncoimmunology.

[85]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[86]  A. Friedman,et al.  An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme , 2009, Molecular Cancer Therapeutics.

[87]  J. Rey,et al.  Early genetic changes involved in low-grade astrocytic tumor development. , 2006, Current molecular medicine.

[88]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[89]  Jayson A. Neil,et al.  Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. , 2013, Advances in biological regulation.

[90]  J. Menten,et al.  Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial , 2012, Cancer Immunology, Immunotherapy.